Drug intelligence / Profile preview

telmisartan + indapamide

Development stage
Unknown
Lead developer
George Medicines
Modality
Small Molecules
Administration
Oral
01

Overview

Telmisartan + indapamide is a fixed-dose combination of two antihypertensive agents used primarily for the treatment of hypertension (high blood pressure). Telmisartan is an angiotensin II receptor blocker (ARB) that works by selectively blocking the binding of angiotensin II to its type 1 receptor in vascular smooth muscle and the adrenal gland, resulting in vasodilation and reduced blood pressure. Indapamide is a thiazide-like diuretic that acts at the distal tubule in the kidney to promote excretion of sodium and water, while also exerting direct vasodilatory effects on blood vessels. The combination effectively lowers blood pressure, reduces cardiovascular risk, and may decrease the risk of stroke, heart attack, and edema. This therapy is indicated as first-line or adjunctive treatment for adults with hypertension[1][4][8].

Brand names
Inditel DTelista-DTelma-DTelmizem DIndilix-TAIndipil T
02

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on telmisartan + indapamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on telmisartan + indapamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call